Drought of approvals gets worse for developers

The long dry spell for new drug approvals has actually worsened a bit. In Vivo notes that the FDA approved six new molecular entities in the first half of the year, down one from the dreadful pace set in 2007. Last year only 16 NMEs made it through, the worst record in a generation at a time that pharma companies have been desperate to add new products to their lineup.

But don't panic yet. In Vivo also notes that there are at east 30 NMEs up for approval at the FDA with a PDUFA date falling prior to New Year's Day. And even though the FDA is increasingly likely to blow off its deadlines, there's still a good chance that 2008 will turn out better than 2007. Let the office pools begin.

- check out the report from In Vivo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.